semaglutide fda changes not allowing compounded The FDA has removed semaglutide injection products (GLP-1) from the Semaglutides Approved for Weight Loss

Research suggests that the early months after stopping semaglutide may represent a higher-risk period for weight regain, with the trajectory often stabilizing somewhat after this initial phase, though weight typically continues to increase beyond six months

The challenge is that when a patient stops taking their medication, the drug is gone but their food environment remains the same, said Dana Small, professor at McGill University and a Canada Excellence Research Chair in metabolism and the brain

[DOI] [PubMed] [Google Scholar] 18.Diamant M, Van Gaal L, Stranks S, et al

corticosteroids are instead used prophylactically to prevent contrast reactions

This shift typically emerges within 23 weeks of starting therapy